Introduction

80
Cytochrome P450 oxidoreductase (POR) is the redox partner of cytochrome P450 proteins located in 6 procedures were carried out according to the manufacturer´s instructions. Data analyses were performed 187 using VariantStudio V2.2.1 (Illumina) and in-house bioinformatic analysis as previously described (34) .
188
The observed variants were evaluated using the Alamut Visual software v2.11 (https://www.interactive-189 biosoftware.com/es/alamut-visual/, which includes following pathogenicity prediction tools: Mutation 
207
Expression of POR proteins in bacteria and membrane purification 208
The human POR WT and R550W mutant proteins (NCBI# NP_000932, UniProt# P16435) were 209 expressed in bacteria using heterologous gene expression (7, 20, 36, 37) . The protocol for recombinant 210 expression of POR variants (N-23 form) and subsequent bacterial membrane purification was based on 211 our previous publications (7, 17, 18, 20, 38) with slight modification. Briefly, plasmid (pET15b) 212 containing cDNAs for WT or mutant POR were obtained from GenScript. The Escherichia coli 213 bacterial strain BL21(DE3) was transformed, and single colonies were selected for growth on 214 carbenicillin plate. For the main shake flask culture, autoinduction media consisting of terrific broth 215 supplemented with 40 mM FeCl3, 4 mM ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4, 2 mM CaCl2, 2 mM 216 CuCl2, 2 mM H3BO3, 0.5 mg/ml riboflavin, 100 µg/ml carbenicillin was used. The cells were grown at 217 37 °C to an optical density (OD) at 600 nm of 0.6, and then the temperature was reduced to 25 °C and 218 further grown for 16 h. The bacterial cells were collected by centrifugation, washed with PBS and 219 slowly stirred for 1 h at 4°C for in 50 mM Tris-acetate (pH 7.6), 0.25 M sucrose, 0.5 mM EDTA, 220 lysozyme (0.2 mg/ml), 1 mM PMSF and 20 U/ml endonuclease to prepare spheroplasts. The 221 spheroplasts were collected by centrifugation at 5000 x g for 20 min; and suspended in 50 mM 222 potassium phosphate (pH 7.6) containing 6 mM Magnesium acetate, 0.1 mM DTT, 20% (v/v) 
263
Flavins were extracted by thermal denaturation of POR proteins and analyzed as described previously 264 (42). POR-WT or POR-R550W (100 µg/ml) were denatured by heating at 95 °C for 10 min in the dark 265 and flavins were separated by centrifugation at 14000 x g for 10 min from the precipitated protein. The 266 fluorescence of the supernatants was measured at pH 7.7 and pH 2.6 to determine FMN and FAD ratio 267 (excitation at 450 nm, emission at 535 nm).
269
Expression and Purification of human CYP19A1
270
The recombinant human CYP19A1 was expressed and purified, as described previously (43) 
290
(CYPEX, Dundee, Scotland, United Kingdom) were reconstituted as described previously (7, (44) (45) (46) 291 and 17α-hydroxylase activity of CYP17A1 was measured by using progesterone as substrate. The
292
reaction mixture consisted of 30 pmol of CYP17A1, 60 pmol of POR, and 14 C labeled progesterone 293 (50000 cpm) in 50 mM potassium phosphate buffer (pH 7.4). The reaction mixture was supplemented 294 with 10 mM magnesium chloride, 6 mM potassium acetate, and 1 mM reduced glutathione.
Progesterone concentration was varied from 0.3 µM to 5 µM for kinetic analysis, and the reaction was 296 initiated by the addition of 2 mM NADPH and incubated for 60 min at 37 °C. Data were fitted based 297 on Michaelis-Menten kinetics using GraphPad Prism (GraphPad Software, La Jolla, CA USA).
299
Assay of cytochrome P450 CYP21A2 enzyme activity supported by WT and POR-R550W
300
Purified recombinant CYP21A2 was used to test the effect of POR-R550W to support the 21-301 hydroxylase activity of CYP21A2. Bacterial membranes containing POR and purified CYP21A2
302
(CYPEX, Dundee, Scotland, United Kingdom) were reconstituted as described previously (7, (44) (45) (46) 303 and 21-hydroxylase activity of CYP21A2 was measured using progesterone as the substrate. The 
311
Cytochrome P450 CYP19A1 enzyme activity supported by WT and POR-R550W
312
Purified recombinant CYP19A1 using the bacterial expression system was used to test the effect of 313 POR-R550W to support the aromatase activity. Aromatase activity was measured by the tritiated water 314 release assay based on an earlier method described by Lephart and Simpson (47) 
326
For NADPH kinetic analysis, androstenedione concentration was kept constant at 100 nM, and NADPH 327 was varied from 62.5-1000 µM.
329
Assay of cytochrome P450 CYP2C9 activity supported by WT and POR-R550W
330
The activity of CYP2C9 supported by WT or mutant POR was tested using in vitro reconstituted system.
331
It consisted of bacterial membranes containing WT/R550W POR, purified CYP2C9 (CYPEX, Dundee, Scotland, United Kingdom) and purified cytochrome b5 at a ratio of 5:1:1 (48 
351
The activity of the major drug-metabolizing enzyme CYP3A4 supported by WT or POR-R550W was 352 tested using the fluorogenic substrate, BOMCC, as described earlier (49). An in-vitro reconstituted 
361
The activity of CYP3A5 supported by WT or POR-R550W was tested using the in-vitro reconstituted 362 system as described above. The purified CYP3A5 (CYPEX, Dundee, Scotland, United Kingdom),
363
WT/mutant POR, and cytochrome b5 were mixed at a ratio of 1:5:1 (48 (Table   390 1). Recommendations related to the stress situation needing glucocorticoid therapy were given to 391 parents.
393
Both POR variants found in patient are observed as rare variants in genome databases
394
The POR variants identified in the patient in this report have been observed as rare variants in the 395 genome databases ( would be unable to support the aromatase activity. We have reported a study of structural stability and 399 sequence conservation analysis to find out which POR variants may be potentially disease-causing (50).
400
Human POR is a 680 amino acid protein that has evolved from ferredoxin and ferredoxin reductase- To differentiate between the POR-WT and POR-R550W, we performed in-silico mutagenesis using the 410
x-ray crystal structure of human POR. Human POR has distinct domains for the binding of 411 NADPH/FAD and FMN (Figure 2A) . The FMN binding domain interacts with the redox partners and 412 is required for electron transfer to partner proteins. The redox equivalents for the electron transfer are 413 provided by NADPH which is used as a substrate by POR and converted to NADP. The R550 residue 414 is not directly at the surface of POR but is located near the NADPH binding pocket (Figure 2B) . In binding to POR (Figure 3) . Since the R550 residue is not directly involved in either the FAD or the 428 FMN binding, loss of flavins suggest an overall instability of protein due to R550W mutation. It has 429 been shown previously that binding of NADPH may affect the FAD/FMN binding in POR, and 430 therefore, R550W mutation in POR may create a conformational change that is less favorable for the 431 binding of FAD as well as FMN.
433
Small molecule Reduction Activity of POR is adversely affected by the R550W mutation.
434
To study the effect of the R550W mutation on POR activity, we expressed WT and POR-R550W in E. 
460
R550W lost almost all 17α-hydroxylase activity of CYP17A1 (Figure 5A, Table 3 ). For the POR-
461
R550W variant, the apparent Vmax was reduced by ~95% without affecting the apparent Km as 462 compared to WT POR. The POR variant R550W showed only 3% residual activity in supporting 463 CYP17A1 as compared to WT POR.
465
The 21-hydroxylase activity of CYP21A2 is severely affected by the R550W mutation in POR
466
The CYP21A2 is involved in the regulation of corticosteroids and is a critical enzyme in the steroid 467 metabolism in human. Defects in CYP21A2 cause the standard form of congenital adrenal hyperplasia 468 and mutation in POR may resemble CYP21A2 deficiency due to adverse effects of a malfunctioning 469 POR on the activities of CYP21A2. The POR-R550W showed highly reduced CYP21A2 activity 470 ( Figure 5B, Table 3 ). The apparent Vmax of POR-R550W was reduced by ~98%. The POR variant 471 R550W showed only 3 % residual activity in supporting CYP21A2 as compared to WT POR.
473
POR mutation R550W causes severe disruption of the aromatase activity of CYP19A1
474
Since the patient showed symptoms of aromatase deficiency as indicated by genital virilization, we 475 were particularly interested in examining the role of R550W mutation in POR on the CYP19A1 activity.
476
Compared to other cytochromes P450 studied in this report, CYP19A1 requires additional steps of 477 electron transfer from POR to complete a single reaction cycle, and therefore, is predicted to be severely 478 affected by changes in POR that affect electron transfer from POR to CYP19A1. The POR-R550W
479
showed a severe effect on CYP19A1 activity (Figure 5C, Table 3) . The apparent Vmax of POR-A similar effect was also observed using MTT reduction assay with a 4.8-fold increase in Km for 518 NADPH for the POR-R550W compared to WT POR (Figure 7B) . We also performed the CYP19A1 519 assay with varying concentrations of NADPH and observed a severe loss of CYP19A1 activity for the 520 POR-R550W (Figure 7C) . In the CYP19A1 assay, a direct evaluation of NADPH oxidation could not 521 be made as the final product was the metabolism of androstenedione into estrone, but the loss of protein-522 protein interaction coupled with the loss of flavins in POR-R550W would severely limit the activity of 523 CYP19A1 due to multiple interactions required for completion of one catalytic cycle.
525
Discussion
526
In this report, we have investigated the cause of CYP19A1 deficiency manifested not by any changes 
549
The patient, an individual with 46, XX DSD, presented signs of prenatal aromatase deficiency as 550 indicated from strong maternal virilization during pregnancy with highly elevated serum T levels at 551 delivery that returned to normal, newborn ambiguous genitalia with elevated T for the female sex, and 552 slightly elevated 17OH-P that progressively diminished. CYP19A1 gene analysis was normal, and it 553 was not until seven years later that compound heterozygous POR gene variants were detected by using a panel of candidate genes for DSD in DNA samples from DSD patients lacking a molecular diagnosis.
555
Clinical and biochemical control at prepubertal age (8 years) revealed normal skeletal growth, normal 556 baseline adrenal function (cortisol and ACTH), although with an elevated 17OH-P.
558
The allele c.73_74delCT/p.Leu25Phefs*93 is predicted to be a null allele resulting from a premature 559 stop codon truncated at amino acid position 93 out of 680 residues in POR protein. Therefore, the 560 protein encoded by the c.1648C>T/p.Arg550Trp allele would be responsible for the patient phenotype.
561
Prenatal and neonatal phenotype predicted a severe aromatase deficiency, whereas the elevated 17-OH-562 P, although with normal cortisol and ACTH, may have indicated the presence of mild 21-hydroxylase 563 and 17,20-lyase deficiencies. The mutation Arg550Trp is located in the NADPH binding region of POR.
564
Computational analysis predicted instability in the NADPH binding region of POR by R550W mutation 565 due to the disruption of hydrogen bonding, which may affect cytochrome P450 activities to a higher 566 degree than small-molecule partners. Computationally predicted the negative effect on several 567 cytochrome P450 activities as well as binding of NADPH were confirmed by experiments using 568 recombinant proteins. These results suggest a pathological effect of POR R550W and a diagnosis of 569 PORD in the patient with p.Arg550Trp/p.Leu25PhefsTer93 in POR. The 46, XX patient and her mother 570 presented prenatal aromatase deficiency; at prepubertal age and without steroid hormone replacement 571 therapy growth is normal and baseline adrenal function is normal (cortisol and ACTH) although the 572 increased level of 17-OH-P demonstrates a mild 21-hydroxylase deficiency. It is predicted that 573 aromatase deficiency will manifest at pubertal age, most probably needing sex hormone replacement 574 therapy and interfering with future fertility while adrenal function will need to be monitored.
576
From the therapeutic perspective, supplementation with steroids is a viable and commonly used option 577 to treat POR deficiency, especially when the loss of exact metabolites can be measured in serum or 
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Assay of CYP2C19 activity was performed to compare POR-WT and POR-R550W by using 20 µM 873 EOMCC as a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given 874 as a percentage of WT activity. Data are shown as mean ± SEM from two experiments performed in 875 triplicates. C. The activity of cytochrome P450 CYP3A4 supported by POR-WT and POR-R550W.
876
Assay of CYP3A4 activity was performed to compare POR-WT and POR-R550W by using 20 µM 877 BOMCC as a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given 878 as a percentage of WT activity. Data are shown as mean ± SEM from two experiments performed in 879 triplicates. D. The activity of cytochrome P450 CYP3A5 supported by POR-WT and POR-R550W.
880
Assay of CYP3A5 activity was performed to compare POR-WT and POR-R550W by using BOMCC 881 as a substrate. Activity with the WT POR was fixed as a hundred percent, and results are given as a 
